Diarrhea in Chronic Inflammatory Bowel Diseases

Gastroenterology Clinics of North America

Volumn 41, Issue 3, 2012, Pages 651-675

  Wenzl, Heimo H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Collagenous colitis; Crohn's disease; Infection; Lymphocytic colitis; Microscopic colitis; Resection; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BISMUTH SALICYLATE; BUDESONIDE; CIPROFLOXACIN; CODEINE; COLESTYRAMINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MORPHINE; PLACEBO; PREDNISOLONE; RIFAXIMIN; VANCOMYCIN;

BACTERIAL INFECTION; BACTERIAL OVERGROWTH; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLLAGENOUS COLITIS; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DRUG RESPONSE; FLUID TRANSPORT; HUMAN; INTESTINE ENDOSCOPY; INTESTINE FISTULA; INTESTINE TRANSIT TIME; ION TRANSPORT; IRRITABLE COLON; LABORATORY TEST; LYMPHOCYTIC COLITIS; MALABSORPTION; MEDICAL HISTORY; MICROSCOPIC COLITIS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDIARRHEALS; BACTERIAL INFECTIONS; BIOPSY; BISMUTH; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BODY WATER; BREATH TESTS; BUDESONIDE; CHOLESTYRAMINE RESIN; COLITIS, MICROSCOPIC; DIARRHEA; ENDOSCOPY, GASTROINTESTINAL; FECES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTESTINAL ABSORPTION; INTESTINAL FISTULA; INTESTINAL MUCOSA; INTESTINES; ION TRANSPORT; MALABSORPTION SYNDROMES; MEDICAL HISTORY TAKING; MESALAMINE; ORGANOMETALLIC COMPOUNDS; PHARMACEUTICAL PREPARATIONS; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; SALICYLATES; SODIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865365357     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.06.006     Document Type: Review

References (132)

1. Frøslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
2. Schiller L.R. Microscopic colitis syndrome: lymphocytic colitis and collagenous colitis. Semin Gastrointest Dis 1999, 10:145-155.
3. Krejs G.J., Fordtran J.S. Physiology and pathophysiology of ion and water movement in the human intestine. Gastrointestinal disease 1978, 297-312. Saunders, Philadelphia, London, Toronto. 2nd edition. M. Sleisinger, J.S. Fordtran (Eds.).
4. Wenzl H.H., Fine K.D., Schiller L.R., et al. Determinants of decreased fecal consistency in patients with diarrhea. Gastroenterology 1995, 108:1729-1738.
5. Debongnie J.C., Phillips S.F. Capacity of the human colon to absorb fluid. Gastroenterology 1978, 74:698-703.
6. Lindström C.G. "Collagenous colitis" with watery diarrhoea: a new entity?. Pathol Eur 1976, 11:87-89.
7. Read N.W., Krejs G.J., Read M.G., et al. Chronic diarrhea of unknown origin. Gastroenterology 1980, 78:264-271.
8. Lazenby A.J., Yardley J.H., Giardiello F.M., et al. Lymphocytic (microscopic) colitis: a comparative histopathologic study, with particular reference to collagenous colitis. Hum Pathol 1989, 20:18-28.
9. Schiller L.R., Sellin J.H. Diarrhea. Sleisenger and Fordtran's gastrointestinal and liver disease 2010, 211-232. WB Saunders, Philadelphia. 9th edition. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
10. Fine K.D., Seidel R.H., Do K. The prevalence, anatomic distribution, and diagnosis of colonic causes of chronic diarrhea. Gastrointest Endosc 2000, 51:318-326.
11. Pardi D.S., Loftus E.V., Smyrk T.C., et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut 2007, 56:504-508.
12. Williams J.J., Kaplan G.G., Makhija S., et al. Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol 2008, 6:35-40.
13. Olesen M., Eriksson S., Bohr J., et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004, 53:346-350.
14. Jarnerot G., Tysk C., Bohr J., et al. Collagenous colitis and fecal stream diversion. Gastroenterology 1995, 109:449-455.
15. Beaugerie L., Pardi D.S. Review article: drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005, 22:277-284.
16. Stewart M., Andrews C.N., Urbanski S., et al. The association of coeliac disease and microscopic colitis: a large population-based study. Aliment Pharmacol Ther 2011, 33:1340-1349.
17. Bohr J., Tysk C., Eriksson S., et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut 1996, 39:846-851.
18. Olesen M., Eriksson S., Bohr J., et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 2004, 53:536-541.
19. Pardi D.S., Ramnath V.R., Loftus E.V., et al. Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol 2002, 97:2829-2833.
20. Fine K.D., Do K., Schulte K., et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol 2000, 95:1974-1982.
21. Schiller L.R. Pathophysiology and treatment of microscopic-colitis syndrome. Lancet 2000, 355:1198-1199.
22. Bo-Linn G.W., Vendrell D.D., Lee E., et al. An evaluation of the significance of microscopic colitis in patients with chronic diarrhea. J Clin Invest 1985, 75:1559-1569.
23. Rask-Madsen J., Grove O., Hansen M.G., et al. Colonic transport of water and electrolytes in a patient with secretory diarrhea due to collagenous colitis. Dig Dis Sci 1983, 28:1141-1146.
24. Burgel N., Bojarski C., Mankertz J., et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002, 123:433-443.
25. Lee E., Schiller L.R., Fordtran J.S. Quantification of colonic lamina propria cells by means of a morphometric point-counting method. Gastroenterology 1988, 94:409-418.
26. Lee E., Schiller L.R., Vendrell D., et al. Subepithelial collagen table thickness in colon specimens from patients with microscopic colitis and collagenous colitis. Gastroenterology 1992, 103:1790-1796.
27. Wang K.K., Perrault J., Carpenter H.A., et al. Collagenous colitis. A clinicopathologic correlation. Mayo Clin Proc 1987, 62:665-671.
28. Ung K.A., Gillberg R., Kilander A., et al. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut 2000, 46:170-175.
29. Ung K.A., Kilander A., Nilsson O., et al. Long-term course in collagenous colitis and the impact of bile acid malabsorption and bile acid sequestrants on histopathology and clinical features. Scand J Gastroenterol 2001, 36:601-609.
30. Schiller L.R., Bilhartz L.E., Santa Ana C.A., et al. Comparison of endogenous and radiolabeled bile acid excretion in patients with idiopathic chronic diarrhea. Gastroenterology 1990, 98:1036-1043.
31. Koskela R.M., Niemelä S.E., Karttunen T.J., et al. Clinical characteristics of collagenous and lymphocytic colitis. Scand J Gastroenterol 2004, 39:837-845.
32. Fine K.D., Lee E.L. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 1998, 114:29-36.
33. Fernandez-Banares F., Salas A., Esteve M., et al. Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am J Gastroenterol 2003, 98:340-347.
34. Chande N., Driman D.K., Reynolds R.P. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol 2005, 40:343-347.
35. Mullhaupt B., Guller U., Anabitarte M., et al. Lymphocytic colitis: clinical presentation in long term course. Gut 1998, 43:629-633.
36. Walter S.A., Münch A., Ost A., et al. Anorectal function in patients with collagenous colitis in active and clinically quiescent phase, in comparison with healthy controls. Neurogastroenterol Motil 2010, 22:534-538.
37. Fine K.D., Schiller L.R. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116:1464-1486.
38. Offner F.A., Jao R.V., Lewin K.J., et al. Collagenous colitis: a study of the distribution of morphological abnormalities and their histological detection. Hum Pathol 1999, 30:451-457.
39. ASGE Standards of Practice Committee, Shen B., Khan K., Ikenberry S.O., et al. The role of endoscopy in the management of patients with diarrhea. Gastrointest Endosc 2010, 71:887-892.
40. Yantiss R.K., Odze R.D. Optimal approach to obtaining mucosal biopsies for assessment of inflammatory disorders of the gastrointestinal tract. Am J Gastroenterol 2009, 104:774-783.
41. Chande N., MacDonald J.K., McDonald J.W. Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials. Am J Gastroenterol 2009, 104:235-241.
42. Fine K.D., Ogunji F., Lee E.L., et al. Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis. Gastroenterology 1999, 116:A880. [abstract].
43. Fernandez-Bañares F., Esteve M., Salas A., et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci 2001, 46:2231-2238.
44. Calabrese C., Fabbri A., Areni A., et al. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol 2007, 22:809-814.
45. Miehlke S., Madisch A., Kupcinskas L., et al. Double-blind, double-dummy, placebo-controlled, multicenter trial of budesonide and measlamine in collagenous colitis [abstract]. Gastroenterology 2012, 142(S1):211.
46. Munck L.K., Kjeldsen J., Philipsen E., et al. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. Scand J Gastroenterol 2003, 38:606-610.
47. Pardi D.S., Loftus E.V., Tremaine W.J., et al. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology 2001, 120:1483-1484.
48. Riddell J., Hillman L., Chiragakis L., et al. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. J Gastroenterol Hepatol 2007, 22:1589-1593.
49. Esteve M., Mahadevan U., Sainz E., et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis 2011, 5:612-618.
50. Münch A., Ignatova S., Ström M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol 2012, 47:59-63.
51. Riaz A.A., Pitt J., Stirling R.W., et al. Restorative proctocolectomy for collagenous colitis. J R Soc Med 2000, 93:261.
52. Yardley J.H., Lazenby A.J., Giardiello F.M., et al. Collagenous, "microscopic," lymphocytic, and other gentler and more subtle forms of colitis. Hum Pathol 1990, 21:1089-1091.
53. Rao S.S.C., Holdsworth C.D., Read N.W. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988, 29:342-345.
54. Harris J., Shields R. Absorption and secretion of water and electrolytes by the intact human colon in diffuse untreated proctocolitis. Gut 1970, 11:27-33.
55. Rask-Madsen J., Hammersgaard E.A., Knudsen E. Rectal electrolyte transport and mucosal permeability in ulcerative colitis and Crohn's disease. J Lab Clin Med 1973, 81:342-353.
56. Allgayer H., Kruis W., Paumgartner G., et al. Inverse relationship between colonic (Na+ + K+)-ATPase activity and degree of mucosal inflammation in inflammatory bowel disease. Dig Dis Sci 1988, 33:417-422.
57. Sandle G.I., Higgs N., Crowe P., et al. Cellular basis for defective electrolyte transport in inflamed human colon. Gastroenterology 1990, 99:97-105.
58. Greig E.R., Boot-Handford R.P., Mani V., et al. Decreased expression of apical Na+ channels and basolateral Na+, K+-ATPase in ulcerative colitis. J Pathol 2004, 204:84-92.
59. Hawker P.C., McKay J.S., Turnberg L.A. Electrolyte transport across colonic mucosa from patients with inflammatory bowel disease. Gastroenterology 1980, 79:508-511.
60. Amasheh S., Barmeyer C., Koch C.S., et al. Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis. Gastroenterology 2004, 126:1711-1720.
61. Sullivan S., Alex P., Dassopoulos T., et al. Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: potential contributors to IBD-associated diarrhea. Inflamm Bowel Dis 2009, 15:261-274.
62. Gitter A.H., Wullstein F., Fromm M., et al. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001, 121:1320-1328.
63. Schmitz H., Barmeyer C., Fromm M., et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999, 116:301-309.
64. Krejs G.J., Fordtran J.S., Fahrenkrug J., et al. Effect of VIP infusion in water and ion transport in the human jejunum. Gastroenterology 1980, 78:722-727.
65. Sandle G.I. Pathogenesis of diarrhea in ulcerative colitis: new views on an old problem. J Clin Gastroenterol 2005, 39(Suppl 2):S49-S52.
66. Gooptu D., Truelove S.C., Warner G.T. Absorption of electrolytes from the colon in cases of ulcerative colitis and in control subjects. Gut 1969, 10:555-561.
67. Head L.H., Heaton J.W., Kivel R.M. Absorption of water and electrolytes in Crohn's disease of the colon. Gastroenterology 1969, 56:571-579.
68. Allan R., Steinberg D.M., Dixon K., et al. Changes in the bidirectional sodium flux across the intestinal mucosa in Crohn's disease. Gut 1975, 16:201-204.
69. Atwell J.D., Duthie H.L. The absorption of water, sodium, and potassium from the ileum of humans showing the effects of regional enteritis. Gastroenterology 1964, 46:16-22.
70. Archampong E.Q., Harris J., Clark C.G. The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro. Gut 1972, 11:880-886.
71. Carethers J.M., McDonnell W.M., Owyang C., et al. Massive secretory diarrhea and pseudo-obstruction as the initial presentation of Crohn's disease. J Clin Gastroenterol 1996, 23:55-59.
72. Zeissig S., Bergann T., Fromm A. Altered ENaC expression leads to impaired sodium absorption in the noninflamed intestine in Crohn's disease. Gastroenterology 2008, 134:1436-1447.
73. Musch M.W., Clarke L.L., Mamah D., et al. T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest 2002, 110:1739-1747.
74. Clayburgh D.R., Musch M.W., Leitges M., et al. Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest 2006, 116:2682-2694.
75. Montgomery R.D., Frazer A.C., Hood C., et al. Studies of intestinal fermentation in ulcerative colitis. Gut 1968, 9:521-526.
76. Rao S.S., Read N.W., Holdsworth C.D. Is the diarrhoea in ulcerative colitis related to impaired colonic salvage of carbohydrate?. Gut 1987, 28:1090-1094.
77. Reddy S.N., Bazzocchi G., Chan S., et al. Colonic motility and transit in health and ulcerative colitis. Gastroenterology 1991, 101:1289-1297.
78. Rao S.S., Read N.W., Brown C., et al. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987, 93:934-940.
79. Rao S.S., Read N.W. Gastrointestinal motility in patients with ulcerative colitis. Scand J Gastroenterol Suppl 1990, 172:22-28.
80. Hofmann A.F. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999, 159(22):2647-2658.
81. Hofmann A.F., Poley J.R. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 1972, 62:918-934.
82. Jacobsen O., Højgaard L., Hylander Møller E., et al. Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. Br Med J (Clin Res Ed) 1985, 290:1315-1318.
83. Poley J.R., Hofmann A.F. Role of fat maldigestion in pathogenesis of steatorrhea in ileal resection. Fat digestion after two sequential test meals with and without cholestyramine. Gastroenterology 1976, 71:38-44.
84. Schiller L.R. Diarrhea following small bowel resection. Advanced therapy of inflammatory bowel diseases 2001, 471-474. BC Decker, Hamilton (Ontario). T.M. Bayless, S.B. Hanauer (Eds.).
85. Andersson H., Isaksson B., Sjögren B. Fat-reduced diet in the symptomatic treatment of small bowel disease: metabolic studies in patients with Crohn's disease and in other patients subjected to ileal resection. Gut 1974, 15:351-359.
86. Fordtran J.S., Bunch F., Davis G.R. Ox bile treatment of severe steatorrhea in an ileectomy-ileostomy patient. Gastroenterology 1982, 82:564-568.
87. Little K.H., Schiller L.R., Bilhartz L.E., et al. Treatment of severe steatorrhea with ox bile in an ileectomy patient with residual colon. Dig Dis Sci 1992, 37:929-933.
88. Gruy-Kapral C., Little K.H., Fordtran J.S., et al. Conjugated bile acid replacement therapy for short-bowel syndrome. Gastroenterology 1999, 116:15-21.
89. Hammer H.F., Fine K.D., Santa Ana C.A., et al. Carbohydrate malabsorption. Its measurement and its contribution to diarrhea. J Clin Invest 1990, 86:1936-1944.
90. Hammer H.F., Santa Ana C.A., Schiller L.R., et al. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989, 84:1056-1062.
91. Caspary W.F. Diarrhoea associated with carbohydrate malabsorption. Clin Gastroenterol 1986, 15:631-655.
92. Schiller L.R. Chronic diarrhea of obscure origin. Diarrheal diseases 1991, 219-238. Elsevier, New York. M. Field (Ed.).
93. Pironi L., Callegari C., Cornia G.L., et al. Lactose malabsorption in adult patients with Crohn's disease. Am J Gastroenterol 1988, 83:1267-1271.
94. Barrett J.S., Irving P.M., Shepherd S.J., et al. Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. Aliment Pharmacol Ther 2009, 30:165-174.
95. Mishkin B., Yalovsky M., Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroenterol 1997, 92:1148-1153.
96. von Tirpitz C., Kohn C., Steinkamp M., et al. Lactose intolerance in active Crohn's disease: clinical value of duodenal lactase analysis. J Clin Gastroenterol 2002, 34:49-53.
97. Eherer A.J., Fordtran J.S. Fecal osmotic gap and pH in experimental diarrhea of various causes. Gastroenterology 1992, 103:545-551.
98. Broe P.J., Cameron J.L. Surgical management of ileosigmoid fistulas in Crohn's disease. Am J Surg 1982, 143:611-613.
99. Levy C., Tremaine W.J. Management of internal fistulas in Crohn's disease. Inflamm Bowel Dis 2002, 8:106-111.
100. Klaus J., Spaniol U., Adler G., et al. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's disease. BMC Gastroenterol 2009, 9:61.
101. Beeken W.L., Kanich R.E. Microbial flora of the upper small bowel in Crohn's disease. Gastroenterology 1973, 65:390-397.
102. Mishkin D., Boston F.M., Blank D., et al. The glucose breath test, a diagnostic test for small bowel stricture (s) in Crohn's disease. Dig Dis Sci 2002, 47:489-494.
103. Castiglione F., Del Vecchio Blanco G., Rispo A., et al. Orocecal transit time and bacterial overgrowth in patients with Crohn's disease. J Clin Gastroenterol 2000, 31:63-66.
104. Mylonaki M., Langmead L., Pantes A., et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004, 16:775-778.
105. Issa M., Vijayapal A., Graham M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
106. Rodemann J.F., Dubberke E.R., Reske K.A., et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
107. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
108. Kornbluth A., Sachar D.B., Practice Parameters Committee of the American College of Gastroenterology Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-523.
109. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
110. Epple H.J. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis 2009, 27:555-559.
111. Goldstein F., DiMarino A.J. Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease. J Clin Gastroenterol 2000, 31:60-62.
112. Fine K.D., Sarles H.E., Cryer B. Diarrhea associated with mesalamine in a patient with chronic nongranulomatous enterocolitis. N Engl J Med 1998, 338:923-925.
113. Marbet U., Schmid I. Severe life-threatening diarrhea caused by azathioprine but not by 6-mercaptopurine. Digestion 2001, 63:139-142.
114. Cox J., Daneshmend T.K., Hawkey C.J., et al. Devastating diarrhoea caused by azathioprine: management difficulty in inflammatory bowel disease. Gut 1988, 29:686-688.
115. Bayless T.M., Harris M.L. Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am 1990, 74:21-28.
116. Stange E.F., Travis S.P., Vermeire S., et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008, 2:1-23.
117. Fine K.D., Fordtran J.S. The effect of diarrhea on fecal fat excretion. Gastroenterology 1992, 102:1936-1939.
118. Nyhlin H., Merrick M.V., Eastwood M.A. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 1994, 35:90-93.
119. Modigliani R., Mary J.Y., Simon J.F., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
120. Van Assche G., Dignass A., Panes J., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
121. Travis S.P., Stange E.F., Lémann M., et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008, 2:24-62.
122. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
123. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
124. Castiglione F., Rispso A., Di Girolamo E., et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1107-1111.
125. Biancone L., Vernia P., Agostini D., et al. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin 2000, 16:14-20.
126. Schiller L.R., Davis G.R., Santa Ana C.A., et al. Studies of the mechanism of the antidiarrheal effect of codeine. J Clin Invest 1982 Nov, 70:999-1008.
127. Schiller L.R., Santa Ana C.A., Morawski S.G., et al. Mechanism of the antidiarrheal effect of loperamide. Gastroenterology 1984, 86:1475-1480.
128. Mainguet P., Fiasse R. Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection. Gut 1977, 18:575-579.
129. DuPont A.W., Sellin J.H. Ileostomy diarrhea. Curr Treat Options Gastroenterol 2006, 9:39-48.
130. Herbst F., Kamm M.A., Nicholls R.J. Effects of loperamide on ileoanal pouch function. Br J Surg 1998, 85:1428-1432.
131. Eherer A.J., Santa Ana C.A., Porter J., et al. Effect of psyllium, calcium polycarbophil, and wheat bran on secretory diarrhea induced by phenolphthalein. Gastroenterology 1993, 104:1007-1012.
132. Griffin M.G., Miner P.B. Review article: refractory distal colitis-explanation and options. Aliment Pharmacol Ther 1996, 10:39-48.